{"id":"33f1575f-4a7c-5277-9a33-d867e69e7bc7","stable_key":"10629adf-a816-5b7b-82db-a76bfbb946f2:bg-apob-and-non-hdl-move-too","predicate":"reduces","statement":"A median dose of 3.5 grams per day of oat beta-glucan significantly lowered LDL-cholesterol by -0.19 with 95% CI -0.23 to -0.14 mmol/l, non-HDL-cholesterol by -0.20 with 95% CI -0.26 to -0.15 mmol/l and apoB by -0.03 with 95% CI -0.05 to -0.02 g/l compared with control interventions, and there was evidence for considerable unexplained heterogeneity in the analysis of LDL-cholesterol with I-squared of 79% and non-HDL-cholesterol with I-squared of 99%.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"6621dcce-7b08-5d5e-9d7e-b88ad064b6c8","mechanism_event_label":"The particle count falls too, not just the cholesterol carried in it.","subject":{"id":"fa30a72e-ed34-59eb-badd-236561a8db88","slug":"oat-beta-glucan","display_name":"Oat mixed-linkage beta-(1->3)/(1->4)-glucan","entity_type_key":"chemical_species"},"object":{"id":"f746a287-c8a1-52d8-b477-fd4df2e1a70f","slug":"circulating-apolipoprotein-b-concentration","display_name":"Circulating apolipoprotein B concentration","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"6621dcce-7b08-5d5e-9d7e-b88ad064b6c8","stable_key":"10629adf-a816-5b7b-82db-a76bfbb946f2:bg-apob-and-non-hdl-move-too-event","event_type":"observed_intervention","label":"The particle count falls too, not just the cholesterol carried in it.","description":"A median dose of 3.5 grams per day of oat beta-glucan significantly lowered LDL-cholesterol by -0.19 with 95% CI -0.23 to -0.14 mmol/l, non-HDL-cholesterol by -0.20 with 95% CI -0.26 to -0.15 mmol/l and apoB by -0.03 with 95% CI -0.05 to -0.02 g/l compared with control interventions, and there was evidence for considerable unexplained heterogeneity in the analysis of LDL-cholesterol with I-squared of 79% and non-HDL-cholesterol with I-squared of 99%.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"ac5f5914-4824-5f9b-93c7-a6b5a52b53af","slug":"ldl-cholesterol-concentration","display_name":"LDL cholesterol concentration","entity_type_key":"cellular_process"},"role":"lowered_measure","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"5f6cc79b-2f53-51de-abe8-0d95693ba03b","slug":"non-hdl-cholesterol-concentration","display_name":"Non-HDL cholesterol concentration","entity_type_key":"cellular_process"},"role":"lowered_measure","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"85090025-4e92-5d9a-8557-80f398f8411e","slug":"coronary-heart-disease","display_name":"Coronary heart disease","entity_type_key":"cellular_process"},"role":"inferred_target","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"fa30a72e-ed34-59eb-badd-236561a8db88","slug":"oat-beta-glucan","display_name":"Oat mixed-linkage beta-(1->3)/(1->4)-glucan","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"f746a287-c8a1-52d8-b477-fd4df2e1a70f","slug":"circulating-apolipoprotein-b-concentration","display_name":"Circulating apolipoprotein B concentration","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/glucan-research/27724985.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"a764416442dac76f7e70e8b6a509b5913693d6a8f7b95cd03beb4567f5b5c9f3\", \"start_char\": 0, \"end_char\": 1647, \"text_sha256\": \"a764416442dac76f7e70e8b6a509b5913693d6a8f7b95cd03beb4567f5b5c9f3\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Systematic review and random-effects meta-analysis of 58 randomised controlled trials in 3974 participants","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Diets enriched with oat beta-glucan at a median 3.5 grams per day for at least three weeks","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Considerable unexplained heterogeneity, with I-squared of 79 percent for LDL and 99 percent for non-HDL cholesterol. These are pooled estimates, not the expected effect of any particular product.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair.","comparator":null,"unit":null,"notes":"","entity":{"slug":"beta-glucan","display_name":"Beta-glucan","entity_type_key":"chemical_species"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The particle count falls too, not just the cholesterol carried in it.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[bg-p27724985] The effect of oat β-glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for CVD risk reduction: a systematic review and meta-analysis of randomised-controlled trials. (2016). https://pubmed.ncbi.nlm.nih.gov/27724985/ DOI: 10.1017/s000711451600341x","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Serum lipoproteins","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"8340476e-a1df-5d78-aded-fcf82692f756","evidence_kind":"source_excerpt","locator":"Lines 502-513","start_line":502,"end_line":513,"excerpt":"### bg-apob-and-non-hdl-move-too\nA median dose of 3.5 grams per day of oat beta-glucan significantly lowered LDL-cholesterol by -0.19 with 95% CI -0.23 to -0.14 mmol/l, non-HDL-cholesterol by -0.20 with 95% CI -0.26 to -0.15 mmol/l and apoB by -0.03 with 95% CI -0.05 to -0.02 g/l compared with control interventions, and there was evidence for considerable unexplained heterogeneity in the analysis of LDL-cholesterol with I-squared of 79% and non-HDL-cholesterol with I-squared of 99%.\nCondition category: normal\nnutrient_topic: Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair.\nplain_language: The particle count falls too, not just the cholesterol carried in it.\norganism: Human\ntissue_or_cell_type: Serum lipoproteins\nexperimental_model: Systematic review and random-effects meta-analysis of 58 randomised controlled trials in 3974 participants\nlimitations: Considerable unexplained heterogeneity, with I-squared of 79 percent for LDL and 99 percent for non-HDL cholesterol. These are pooled estimates, not the expected effect of any particular product.\nexposure: Diets enriched with oat beta-glucan at a median 3.5 grams per day for at least three weeks\nevidence_span: {\"source_cache\": \"artifacts/glucan-research/27724985.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"a764416442dac76f7e70e8b6a509b5913693d6a8f7b95cd03beb4567f5b5c9f3\", \"start_char\": 0, \"end_char\": 1647, \"text_sha256\": \"a764416442dac76f7e70e8b6a509b5913693d6a8f7b95cd03beb4567f5b5c9f3\"}\n[bg-p27724985] The effect of oat β-glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for CVD risk reduction: a systematic review and meta-analysis of randomised-controlled trials. (2016). https://pubmed.ncbi.nlm.nih.gov/27724985/ DOI: 10.1017/s000711451600341x","model_system":"Systematic review and random-effects meta-analysis of 58 randomised controlled trials in 3974 participants","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [bg-p27724985] The effect of oat β-glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for CVD risk reduction: a systematic review and meta-analysis of randomised-controlled trials. (2016). https://pubmed.ncbi.nlm.nih.gov/27724985/ DOI: 10.1017/s000711451600341x","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"74dc223d-8289-57bf-a731-d220fa017c1e","stable_key":"import-10629adf-a816-5b7b-82db-a76bfbb946f2","title":"Beta-glucan: a structural family rather than an agent, what decides whether a bound glucan actually signals, the complement route that a cereal and a yeast preparation share, and the unequal human evidence behind each (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"7c62f2d2f8d99b650e6dc26a505b0f053ae1c8bdb38099d4dfc0771f65287461","revision_id":"a53bb794-0a4b-525d-9cf7-22b46a5403b0","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}